Early experience with osimertinib as second line treatment for EGFR mutated non-small cell lung cancer (NSCLC) and detecting T790M mutations from plasma circulating tumour DNA (ctDNA)

Lewis P. J.; Cox R. A.

首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >Early experience with osimertinib as second line treatment for EGFR mutated non-small cell lung cancer (NSCLC) and detecting T790M mutations from plasma circulating tumour DNA (ctDNA)

【24h】

Early experience with osimertinib as second line treatment for EGFR mutated non-small cell lung cancer (NSCLC) and detecting T790M mutations from plasma circulating tumour DNA (ctDNA)

机译：早期的Esimertinib作为EGFR突变非小细胞肺癌（NSCLC）的第二线治疗，并从等离子体循环肿瘤DNA（CTDNA）检测T790M突变

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Lung cancer: Journal of the International Association for the Study of Lung Cancer 》 |2017年第1期| 共1页
作者
Lewis P. J.; Cox R. A.;
展开▼
作者单位

Royal United Hosp NHS Fdn Trust Oncol Bath Avon England;

Royal United Hosp NHS Fdn Trust Oncol Bath Avon England;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学 ;
关键词

相似文献

外文文献
中文文献
专利

1. Early experience with osimertinib as second line treatment for EGFR mutated non-small cell lung cancer (NSCLC) and detecting T790M mutations from plasma circulating tumour DNA (ctDNA) [J] . Lewis P. J., Cox R. A. Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2017 ,第Suppla1期

机译：早期的Esimertinib作为EGFR突变非小细胞肺癌（NSCLC）的第二线治疗，并从等离子体循环肿瘤DNA（CTDNA）检测T790M突变
2. Co‐mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer [J] . Puyuan Xing, Xiaohong Han, Sha Wang, Journal of cellular and molecular medicine. . 2019 ,第10期

机译：奥美替尼治疗T790M突变型肺癌期间循环肿瘤DNA（ctDNA）的共突变评估
3. P2.13-25 Analysis of EGFR Mutations Using Circulating Tumour DNA (ctDNA) in Non-Small Cell Lung Cancer Patients in North East Scotland [J] . P. Scott, C. Clark, K. Kerr, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2018 ,第10期

机译：P2.13-25在苏格兰东北东部非小细胞肺癌患者中使用循环肿瘤DNA（CTDNA）的EGFR突变分析
4. Enumeration and ALK Investigation of Circulating Tumor Cells in Non-Small Cell Lung Cancer (NSCLC) Patients Using an Effective In Vivo Technology, the GILUPI CellCollector? [C] . Klaus Luecke, Lukasz Gasiorowski, Stefanie Herold, International Molecular Medicine Tri-Conference. . 2015

机译：使用有效的体内技术（Gilupi Cellcollector
5. Pre-Treatment Radiomics Models for Clinical Outcomes in Early-Stage Non-Small Cell Lung Cancer (NSCLC) [D] . Shaffer, Nathan Allen. 2021

机译：早期非小细胞肺癌临床结果的预处理辐射瘤模型（NSCLC）
6. A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2 [O] . Cheol-Kyu Park, Hyun-Ju Cho, Yoo-Duk Choi, 2019

机译：从循环肿瘤DNA中检测到的奥西替尼在EGFR T790M突变的非小细胞肺癌二线治疗中的II期试验：LiquidLung-O-Cohort 2
7. Co‐mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer [O] . Puyuan Xing, Xiaohong Han, Sha Wang, 2019

机译：循环肿瘤DNA（CTDNA）在T790M突变体肺癌中的循环肿瘤DNA（CTDNA）的共鸣评价

Early experience with osimertinib as second line treatment for EGFR mutated non-small cell lung cancer (NSCLC) and detecting T790M mutations from plasma circulating tumour DNA (ctDNA)

著录项

相似文献

相关主题

期刊订阅